Gilead Sciences, Inc. (BVMF:GILD34)

Market Cap	987.55B +44.1%
Revenue (ttm)	155.02B +2.8%
Net Income	43.22B +6,336.5%
EPS	34.23 +6,514.1%
Shares Out	n/a
PE Ratio	22.85
Forward PE	18.74
Dividend	5.87 (1.48%)
Ex-Dividend Date	Dec 12, 2025

Volume	1
Average Volume	174
Open	395.48
Previous Close	393.42
Day's Range	395.48 - 395.48
52-Week Range	273.51 - 395.48
Beta	0.39
RSI	75.75
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: GILD34

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD